Investors looking for more hot stock market news from Monday can keep reading. RAPT stock was up 111.1% as of Monday afternoon. The adverse events that did occur were only mild or moderate in nature. In addition to this, RAPT Therapeutics notes there were no severe adverse events connected to the study. More than a year into the pandemic, only a handful of repurposed therapeutics have been approved to treat COVID-19: dexamethasone in the UK and Japan Avigan (favilavir) in China, Italy and Russia Veklury (remdesivir) in the US, UK and Japan and Lagevrio (molnupiravir) in the UK.
RAPT THERAPEUTICS TRIAL
We look forward to advancing RPT193 to a Phase 2b trial in atopic dermatitis and a Phase 2a trial in asthma.” “These data strongly support the potential of RPT193 as a safe, once-daily, oral treatment for patients with atopic dermatitis which would be an attractive therapeutic alternative ahead of injectable drugs. For perspective, patients in the placebo group only reported a 9.6% improvement.īrian Wong, M.D., Ph.D., president and CEO of RAPT Therapeutics, said this about the positive news boosting the company’s stock higher today. That includes patients taking RPT193 reporting a 53.2% improvement. RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. 18, 2021 (GLOBE NEWSWIRE) - RAPT Therapeutics, Inc.
RAPT THERAPEUTICS SKIN
In the two weeks following the four weeks of treatments, further improvements were seen. RAPT Therapeutics Announces Upcoming Oral Presentation of RPT193 Phase 1b Data at the 4th Inflammatory Skin Disease Summit. RAPT Therapeutics notes that the positive news continues beyond just the treatment period. For comparison, placebo improvement was 17%. RAPT Therapeutics, Inc., a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small. The Company is focused on discovering, developing and. After four weeks of treatment, patients taking RPT193 saw an improvement of 36.3% on the Eczema Area and Severity Index score. is a clinical-stage immunology-based biopharmaceutical company. The company’s stock price has collected 7.24 of gains in the last five trading sessions. The clinical trial included a total of 31 patients suffering from moderate-to-severe atopic dermatitis. (NASDAQ:RAPT) went down by -5.86 from its latest closing price compared to the recent 1-year high of 43.26.
The recent results come from a Phase 1b clinical trial of the drug. RPT193 is the company’s treatment in development designed to treat patients suffering from moderate-to-severe atopic dermatitis.
0 kommentar(er)
